Establishing a MoCA cut-off point for cognitive impairment detection in Mexican people living with Parkinson's disease: A comprehensive assessment (level II) approach.

Background: Cognitive impairment (CI) is a prevalent and debilitating non-motor symptom of Parkinson's disease (PD), affecting around 25-30 % of the people living with PD (PwP). The Montreal Cognitive Assessment (MoCA) is a widely used tool for detecting CI. Yet, its optimal cut-off score for PwP, particularly within specific populations such as the Mexican demographic, remains inadequately defined.

Association between alterations in sleep spindles and cognitive decline in persons with Parkinson's disease.

Background: Sleep macro and microstructural features have a relevant role for cognition. Although alterations in sleep macrostructure have been reported in persons with neurodegenerative disorders, including Parkinson's disease (PD), it is unknown whether there is a relationship between alterations in microstructure (sleep spindles) and global cognitive deficits in this disease.

Objective: To explore the association between the macro and microstructure of sleep (sleep spindles) and the general cognitive state in persons with PD.

A Characterization of Central Auditory Processing in Parkinson's Disease.

Background: Research indicates that people with Parkinson's disease (PwPs) may experience challenges in both peripheral and central auditory processing, although findings are inconsistent across studies. Due to the diversity of auditory measures used, there is a need for standardized, replicable hearing assessments to clarify which aspects of audition are impacted in PWPs and whether they are linked to motor and non-motor symptoms.

Objective: To characterize auditory processes and their possible alteration in PwPs.

Levodopa versus levodopa sparing in early parkinson's disease: can we meet halfway?

Monotherapy is the recommended initial treatment for early Parkinson's disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations. Several factors should be considered when selecting the optimal treatment, such as disease severity, disease duration, age, activity level, and the risk of developing motor and non-motor complications.

Building national patient registries in Mexico: insights from the MexOMICS Consortium.

Objective: To introduce MexOMICS, a Mexican Consortium focused on establishing electronic databases to collect, cross-reference, and share health-related and omics data on the Mexican population.

Methods: Since 2019, the MexOMICS Consortium has established three electronic-based registries: the Mexican Twin Registry (TwinsMX), Mexican Lupus Registry (LupusRGMX), and the Mexican Parkinson's Research Network (MEX-PD), designed and implemented using the Research Electronic Data Capture web-based application. Participants were enrolled through voluntary participation and on-site engagement with medical specialists.